Nurse Practitioner Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Sam Simon

Registered Nurse, Psychiatric/Mental Health, Adult Philadelphia, PA Nurse Practitioner

NPI 1326769399 CMS profile 11380728

4200 Monument Road, Outpatient Building, Philadelphia, PA 19131

Open in the dashboard

General payments

$1,599

76 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Sam Simon of Philadelphia, PA is reported in the CMS Open Payments database as having received $1,599 across 76 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 90th percentile of Registered Nurse, Psychiatric/Mental Health, Adult profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $680 30
2024 General $588 29
2023 General $331 17

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Sam Simon
  • Registered Nurse, Psychiatric/Mental Health, Adult median
  • Middle half of Registered Nurse, Psychiatric/Mental Health, Adult
  • National median

In program year 2025, general payments to Sam Simon were reported at $680. Among 96 Registered Nurse, Psychiatric/Mental Health, Adult profiles paid that year, the median was $121 and the middle half received between $39 and $265.

Show as a table
Year Sam Simon Registered Nurse, Psychiatric/Mental Health, Adult median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $0 $108 $31–$328 $132
2022 $0 $99 $22–$306 $149
2023 $331 $99 $43–$313 $160
2024 $588 $119 $30–$319 $164
2025 $680 $121 $39–$265 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Neurocrine Biosciences, Inc. $452 17 payments
  2. AbbVie, Inc. $335 18 payments
  3. Otsuka America Pharmaceutical, Inc. $264 15 payments
  4. E.R. Squibb & Sons, L.L.C. $138 5 payments
  5. Teva Pharmaceuticals USA, Inc. $135 7 payments
  6. ITI, Inc. $125 6 payments
  7. Almatica Pharma LLC $50 3 payments
  8. Janssen Pharmaceuticals, Inc $48 3 payments
  9. Vanda Pharmaceuticals Inc. $30 1 payment
  10. Alkermes, Inc. $23 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Food and Beverage $1,599 76 payments
Products named General payments · program years 2023–2025
  1. INGREZZA $452 17 payments
  2. REXULTI $206 12 payments
  3. VRAYLAR Neuroscience $195 10 payments
  4. VRAYLAR Neuroscience $140 8 payments
  5. CAPLYTA $125 6 payments
  6. ABILIFY MAINTENA $120 7 payments
  7. UZEDY $113 6 payments
  8. COBENFY $107 4 payments
  9. LOREEV XR $50 3 payments
  10. INVEGA SUSTENNA $48 3 payments
  11. Other $190 9 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 51 drugs

Part D claims

4,305

Median for Nurse Practitioner: 389

Drug cost

$162,365

Median for Nurse Practitioner: $21,885

Branded share of claims

15.5%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Abilify Maintena Aripiprazole Brand 23 $51,927
Vraylar Cariprazine Hcl Brand 20 $27,973
Lurasidone Hcl Generic 78 $23,556
Aripiprazole Generic 274 $10,290
Bupropion Xl Bupropion Hcl Brand 223 $3,763
Quetiapine Fumarate Generic 313 $3,469
Duloxetine Hcl Generic 177 $3,287
Paliperidone Er Paliperidone Brand 13 $2,963
Trazodone Hcl Generic 347 $2,254
Buspirone Hcl Generic 187 $2,153

The 10 drugs with the highest cost, of 51 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 10 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VRAYLAR
  • AbbVie, Inc. $156
$156 20 —
INGREZZA
  • Neurocrine Biosciences, Inc. $102
$102 — —
CAPLYTA
  • ITI, Inc. $90
$90 — —
UZEDY
  • Teva Pharmaceuticals USA, Inc. $49
$49 — —
INVEGA SUSTENNA
  • Janssen Pharmaceuticals, Inc $48
$48 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 10 in the dashboard with a free account

Records

76 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Registered Nurse, Psychiatric/Mental Health, Adult in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record